Positions

Overview

  • David G. Warnock, MD is the Director of the Division of Nephrology and Professor of Medicine and Physiology at the University of Alabama at Birmingham. He graduated from the University of California at Berkeley and received his MD degree from the University of California, San Francisco. His clinical training was completed at the University of California, San Francisco, including a 1 year research fellowship with Isidore Edelman, MD in the Cardiovascular Research Institute. Following a fellowship with Maurice Burg, MD at the NIH, Dr. Warnock returned to UCSF as a faculty member. He served as the Section Chief at the San Francisco VA Medical Center during the last 5 years of his appointment at UCSF. Following a sabbatical with Bernard Rossier, MD at the Institute of Pharmacology in Lausanne, Switzerland, Dr. Warnock was recruited to UAB as the Director of Nephrology in 1988. Since May 1, 2005, Dr. Warnock has also served at the Director of the Office of Human Research at UAB. Dr. Warnock’s research interests include acid-base physiology, sodium transport mechanisms, chronic kidney disease, and inherited renal diseases. He is a member of the American Society for Clinical Investigation, American Association of Physicians, American Physiologic Society, ASN, NFK and ISN. He is currently serving as the President of the National Kidney Foundation.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease 2019
    2019 JC viruria is associated with reduced risk of diabetic kidney disease 2019
    2019 Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints 2019
    2019 Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium 2019
    2019 Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease 2019
    2019 Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease 2019
    2018 Serum albumin concentration and risk of end-stage renal disease: The REGARDS study 2018
    2018 Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study 2018
    2018 Dietary Oxidative Balance Scores and Biomarkers of Inflammation among Individuals with and without Chronic Kidney Disease 2018
    2018 Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study 2018
    2018 Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery 2018
    2017 Evaluation of Renal Function and Renal Risk in the Twenty-First Century 2017
    2017 Global cardiovascular and renal outcomes of reduced GFR 2017
    2017 Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria 2017
    2017 Conjunctival lymphangiectasia associated with classic Fabry disease 2017
    2017 The pressing need for real-time risk assessment of hospital-acquired acute kidney injury 2017
    2017 The Fault Is Not in Our Stars but May Be in Our Embryos: Glomerular Number in Low Birth Weight Babies 2017
    2017 Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference 2017
    2017 The global burden of chronic kidney disease: Estimates, variability and pitfalls 2017
    2016 Urinary podocyte loss is increased in patients with fabry disease and correlates with clinical severity of fabry nephropathy 2016
    2016 Serum Creatinine Trajectories for Community- versus Hospital-Acquired Acute Kidney Injury 2016
    2016 Epilogue: UAB Symposium November 2015 2016
    2016 Estimated Glomerular Filtration Rate: Fit for What Purpose? 2016
    2016 Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry 2016
    2016 Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults 2016
    2016 Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta 2016
    2016 Competing risks: you only die once 2016
    2016 Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: Data from the Fabry Registry 2016
    2016 Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration 2016
    2016 Sulfenic acid modification of endothelin b receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia 2016
    2016 The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old 2016
    2016 Association of reduced eGFR and albuminuria with serious fall injuries among older adults 2016
    2016 Categories of hospital-associated acute kidney injury: Time course of changes in serum creatinine values 2016
    2016 Gastrointestinal involvement in Fabry disease: So important, yet often neglected 2016
    2016 Past decline versus current EGFR and subsequent mortality risk 2016
    2016 Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study 2016
    2015 Validation of an albuminuria self-assessment tool in the Multi-Ethnic Study of Atherosclerosis (MESA) 2015
    2015 Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase A in fabry patients when co-administered with infused agalsidase 2015
    2015 Appendiceal tissue confirmation of Fabry's disease 2015
    2015 Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data 2015
    2015 Oral anticoagulants and risk of nephropathy 2015
    2015 Rapid immunochromatographic detection of serum anti-α-Galactosidase a antibodies in fabry patients after enzyme replacement therapy 2015
    2015 Late onset variants in Fabry disease: Results in high risk population screenings in Argentina 2015
    2015 Obesity, metabolic health, and the risk of end-stage renal disease 2015
    2015 A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury 2015
    2015 Amiloride: The “new” renal tonic? 2015
    2015 Antiproteinuric therapy and Fabry nephropathy: Factors associated with preserved kidney function during agalsidase-beta therapy 2015
    2015 Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial 2015
    2015 Cognitive function in adults aging with fabry disease: A case–control feasibility study using telephone-based assessments 2015
    2015 Contrasting cholesterol management guidelines for adults with CKD 2015
    2015 Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria 2015
    2015 Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with fabry disease 2015
    2015 The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial 2015
    2015 The furosemide stress test and predicting AKI outcomes 2015
    2015 Validation study of medicare claims to identify older US adults with CKD using the reasons for geographic and racial differences in stroke (REGARDS) study 2015
    2014 Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry 2014
    2014 Meta-Analysis of Genome-Wide Association Studies in African Americans Provides Insights into the Genetic Architecture of Type 2 Diabetes 2014
    2014 Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411 2014
    2014 Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice 2014
    2014 Association of inflammatory and endothelial cell activation biomarkers with acute kidney injury after sepsis 2014
    2014 Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells. 2014
    2014 Dietary patterns and risk of death and progression to ESRD in individuals with CKD: A cohort study 2014
    2014 Fabry disease: Dose matters 2014
    2014 Incident ESRD and treatment-resistant hypertension: The reasons for geographic and racial differences in stroke (REGARDS) study 2014
    2014 Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl 2014
    2014 Nondisease-specific problems and all-cause mortality among older adults with CKD: The REGARDS study 2014
    2014 Pathophysiology and Treatment of Resistant Hypertension: The Role of Aldosterone and Amiloride-Sensitive Sodium Channels 2014
    2014 Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar 2014
    2014 Similar names for similar biologics 2014
    2013 Metabolic subtypes and risk of mortality in normal weight, overweight, and obese individuals with CKD 2013
    2013 Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: Data from the Fabry Registry 2013
    2013 Prevalence of apparent treatment-resistant hypertension among individuals with CKD 2013
    2013 Association between urinary albumin excretion and coronary heart disease in black vs white adults 2013
    2013 Fibrosis: A key feature of Fabry disease with potential therapeutic implications 2013
    2013 High-Sensitivity C-Reactive Protein and Risk of Sepsis 2013
    2013 Pharmacovigilance and biosimilars: Considerations, needs and challenges 2013
    2013 Cardiovascular risk factors in CKD associate with both ESRD and mortality 2013
    2013 Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injury 2013
    2013 Genetic disorders of potassium homeostasis 2013
    2013 The amiloride-sensitive endothelial sodium channel and vascular tone 2013
    2013 Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study 2013
    2013 Geographic variation in CKD prevalence and ESRD incidence in the united states: Results from the reasons for geographic and racial differences in stroke (REGARDS) study 2013
    2013 Healthy behaviors, risk factor control and awareness of chronic kidney disease 2013
    2013 Low hemoglobin levels and recurrent falls in U.S. Men and Women: Prospective findings from the REasons for Geographic and racial differences in stroke (REGARDS) cohort 2013
    2013 Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON) 2013
    2013 Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers 2013
    2012 Low income and albuminuria among REGARDS (Reasons for geographic and racial differences in stroke) study participants 2012
    2012 Racial differences in albuminuria, kidney function, and risk of stroke 2012
    2012 Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease 2012
    2012 Arrhythmias in Fabry cardiomyopathy 2012
    2012 Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease 2012
    2012 Critical care nephrology: Management of acid-base disorders with CRRT 2012
    2012 Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end- stage renal disease and peritoneal dialysis 2012
    2012 Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate 2012
    2012 Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for fabry disease 2012
    2012 Acute kidney injury and mortality in hospitalized patients 2012
    2012 Design of clinical trials in AKI: A report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings 2012
    2012 Design of clinical trials in acute kidney injury: A report from an NIDDK workshop-prevention trials 2012
    2012 Design of clinical trials in acute kidney injury: Report from an NIDDK workshop on trial methodology 2012
    2012 Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry 2012
    2012 Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. 2012
    2012 Association of family history of ESRD, prevalent albuminuria, and reduced GFR with incident esrd 2012
    2012 Incidence of stroke symptoms among adults with chronic kidney disease: Results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study 2012
    2012 Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation 2012
    2011 Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications 2011
    2011 The authors reply 2011
    2011 Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States 2011
    2011 Chronic kidney disease and risk of death from infection 2011
    2011 Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality 2011
    2011 Albuminuria and racial disparities in the risk for ESRD 2011
    2011 Membranous glomerulopathy in an adult patient with X-linked agammaglobulinemia receiving intravenous gammaglobulin 2011
    2011 Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) study 2011
    2011 Development and validation of a self-assessment tool for albuminuria: Results from the reasons for geographic and racial differences in stroke (REGARDS) study 2011
    2011 Inflammation biomarkers and risk of all-cause mortality in the reasons for geographic and racial differences in stroke cohort 2011
    2011 Bardoxolone methyl and kidney function in CKD with type 2 diabetes 2011
    2011 Warfarin-related nephropathy: Another newly recognized complication of an old drug 2011
    2011 A distinct urinary biomarker pattern characteristic of female fabry patients that mirrors response to enzyme replacement therapy 2011
    2011 Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD 2011
    2011 Vitamin D receptor activation: Implications for daily practice 2011
    2011 Detection of chronic kidney disease with creatinine, cystatin c, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality 2011
    2011 The fabry cardiomyopathy: Models for the cardiologist 2011
    2011 Association of chronic kidney disease with atrial fibrillation among adults in the United States REasons for Geographic and Racial Differences in Stroke (REGARDS) study 2011
    2011 Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease 2011
    2010 How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? 2010
    2010 Hemoglobin concentration and cognitive impairment in the renal REasons for Geographic And Racial Differences in Stroke (REGARDS) study 2010
    2010 Prognostic indicators of renal disease progression in adults with fabry disease: Natural history data from the Fabry Registry 2010
    2010 Blood pressure, proteinuria and nephropathy in Fabry disease 2010
    2010 Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study 2010
    2010 Associations of dietary fat with albuminuria and kidney dysfunction 2010
    2010 Introduction to the Third Annual Rostand Vitamin D Symposium 2010
    2010 The natural history of fabry disease 2010
    2010 Poverty and racial disparities in kidney disease: The REGARDS study 2010
    2010 Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis 2010
    2010 Enzyme replacement therapy for Fabry's disease 2010
    2010 A roadmap for biomarker qualification 2010
    2010 Physical and psychological burden of chronic kidney disease among older adults 2010
    2010 Enzyme replacement therapy and fabry nephropathy 2010
    2010 Introduction to focus on Fabry nephropathy: Biomarkers, progression, and disease severity 2010
    2010 A validated disease severity scoring system for Fabry disease 2010
    2010 End-stage renal disease in patients with Fabry disease: Natural history data from the Fabry Registry 2010
    2010 Acute kidney injury in sepsis: Questions answered, but others remain 2010
    2010 Acute kidney injury: Where's the consensus about its definition 2010
    2010 QT prolongation is an independent predictor of mortality in end-stage renal disease 2010
    2010 Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN) 2010
    2009 Mineralocorticoid receptor blockers and chronic kidney disease 2009
    2009 Exploration of anaemia as a progression factor in African Americans with cardiovascular disease 2009
    2009 Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy 2009
    2009 Nephropathy in Fabry disease: The importance of early diagnosis and testing in high-risk populations 2009
    2009 The A563T variation of the renal epithelial calcium channel TRPV5 among African Americans enhances calcium influx 2009
    2009 Correlates of anemia in American Blacks and Whites: The REGARDS Renal Ancillary study 2009
    2008 Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease 2008
    2008 Chronic kidney disease is often unrecognized among patients with coronary heart disease: The REGARDS cohort study 2008
    2008 Introduction to vitamin D symposium, March 14, 2008 2008
    2008 Kidney Function and Cognitive Impairment in US Adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study 2008
    2008 Racial Differences in the Competing Risks of Mortality and ESRD After Acute Myocardial Infarction 2008
    2008 Authors' response 2008
    2008 Evaluation and initial management of acute kidney injury 2008
    2008 Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults 2008
    2008 Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified delphi process 2008
    2008 Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy 2008
    2008 Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction 2008
    2008 Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry 2008
    2007 Enzyme Replacement Therapy and Fabry Kidney Disease 2007
    2007 Membrane tension modulates the effects of apical cholesterol on the renal epithelial sodium channel 2007
    2007 Reliability of urinary albumin, total protein, and creatinine assays after prolonged storage: The family investigation of nephropathy and diabetes 2007
    2007 Improving outcomes from acute kidney injury: Report of an initiative 2007
    2007 WNK4-mediated regulation of renal ion transport proteins 2007
    2007 Predictors of Survival in Patients With End-Stage Renal Disease Evaluated for Kidney Transplantation 2007
    2007 An intermediate-conductance Ca2+-activated K+ channel mediates B lymphoma cell cycle progression induced by serum 2007
    2007 Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β 2007
    2007 Improving outcomes of acute kidney injury: Report of an initiative 2007
    2007 Improving Outcomes From Acute Kidney Injury: Report of an Initiative 2007
    2007 Improving outcomes from acute kidney injury 2007
    2007 Enzyme replacement therapy and fabry kidney disease: Quo vadis? 2007
    2007 Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study 2007
    2007 Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury 2007
    2007 Agalsidase-beta therapy for advanced fabry disease: A randomized trial 2007
    2007 Improving outcomes from acute kidney injury (AKI): Report on an initiative 2007
    2006 Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil 2006
    2006 Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement 2006
    2006 Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study 2006
    2006 Chronic kidney disease: a public health problem that needs a public health action plan. 2006
    2006 Recent progress in inherited kidney diseases 2006
    2006 Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex 2006
    2006 Chronic kidney disease: A public health problem that needs a public health action plan 2006
    2006 Diagnosis and management of kidney involvement in fabry disease 2006
    2006 Survival advantage of black patients with kidney disease after acute myocardial infarction. 2006
    2005 Renal sodium handling: The role of the epithelial sodium channel 2005
    2005 Time-dependent associations between iron and mortality in hemodialysis patients 2005
    2005 Towards a definition and classification of acute kidney injury 2005
    2005 Delay in time to receipt of thrombolytic medication among medicare patients with kidney disease 2005
    2005 K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease: Work group membership 2005
    2005 Prevalence of chronic kidney disease and anemia among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study: Baseline results 2005
    2005 Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension 2005
    2005 Fabry disease: Diagnosis and management, with emphasis on the renal manifestations 2005
    2005 Importance of Proteinuria and Its Treatment in Patients with Fabry Disease Receiving Enzyme Replacement Therapy 2005
    2005 Importance of Proteinuria and Its Treatment in Patients with Fabry Disease Receiving Enzyme Replacement Therapy 2005
    2004 Hyperkalemia after the Publication of RALES [1] (multiple letters) 2004
    2004 Vascular grafts for hemodialysis: Types, sites and techniques 2004
    2004 Inclusion of albumin as a target in therapy guidelines: Guidelines for chronic kidney disease 2004
    2004 Acidic ATP activates lymphocyte outwardly rectifying chloride channels via a novel pathway 2004
    2004 Sodium and potassium handling by the aldosterone-sensitive distal nephron: The pivotal role of the distal and connecting tubule 2004
    2004 Steroids and exogenous γ-ENaC subunit modulate cation channels formed by α-ENaC in human B lymphocytes 2004
    2004 Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety 2004
    2004 Hypertension. 2004
    2004 Oxidative Stress in Hypertension and Chronic Kidney Disease: Role of Angiotensin II 2004
    2003 WNK kinases, distal tubular ion handling and hypertension 2003
    2003 Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport 2003
    2003 Interventional nephrology: Work in progress 2003
    2003 Familial hyperkalemic hypertension: Phenotypic analysis in a large family with the WNK1 deletion mutation 2003
    2003 Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (≥250 mg) administration 2003
    2003 Hereditary disorders of potassium homeostasis 2003
    2003 Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States 2003
    2003 Sodium ferric gluconate complex in hemodialysis patients. Ii. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients 2003
    2002 Epithelial sodium channels expressed in Xenopus oocytes are activated by cyclic-AMP 2002
    2002 ATP masks stretch activation of epithelial sodium channels in A6 distal nephron cells 2002
    2002 Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT1 receptors 2002
    2002 Renal genetic disorders related to K+ and Mg2+ 2002
    2002 Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC) 2002
    2002 Genetic forms of renal potassium and magnesium wasting 2002
    2002 Issues related to iron replacement in chronic kidney disease 2002
    2002 Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran 2002
    2001 Liddle's syndrome: Genetics and mechanisms of Na+ channel defects 2001
    2001 Localization and functional characterization of NA+/H+ exchanger isoform NHE4 in rat thick ascending limbs 2001
    2001 Genetic forms of human hypertension 2001
    2001 An Alu cassette in the human epithelial sodium channel 2001
    2001 Genetic renal tubular disorders of renal ion channels and transporters 2001
    2001 Liddle syndrome: Genetics and mechanisms of Na+ channel defects 2001
    2001 Nitric oxide and Bartter and Gitelman syndromes 2001
    2001 Prevention, protection, and the intrarenal renin-angiotensin systems 2001
    2001 Simplified citrate anticoagulation for continuous renal replacement therapy 2001
    2000 Disorders of the epithelial Na+ channel in Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type 1 2000
    2000 Interaction of syntaxins with epithelial ion channels 2000
    2000 Macula densa Na+/H+ exchange activities mediated by apical NHE2 and basolateral NHE4 isoforms 2000
    2000 Low renin hypertension in the next millennium 2000
    2000 Aldosterone-related genetic effects in hypertension 2000
    1999 Hypertension 1999
    1999 Interaction of syntaxins with the amiloride-sensitive epithelial sodium channel 1999
    1999 Mechanisms of Disease: Genetic disorders of renal electrolyte transport 1999
    1999 Accessory factors and the regulation of epithelial sodium channel activity 1999
    1999 Expression of transfected human Na+/H+ exchanger (NHE-1) in the basolateral membrane of opossum kidney cells 1999
    1999 Low-renin and nonmodulating essential hypertension 1999
    1999 Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure 1999
    1999 Regulation by PKC isoforms of Na+/H+ exchanger in luminal membrane vesicles isolated from cortical tubules 1999
    1999 Regulation of endosomal acidification via G1-type protein 1999
    1999 T594M mutation in the ENaC β subunit and low-renin hypertension in blacks 1999
    1999 The epithelial sodium channel in hypertension 1999
    1999 αENaC: Leading the charge 1999
    1998 Immunolocalization of the Na+/H+ exchanger isoform NHE2 in rat kidney 1998
    1998 Cloning and functional studies of splice variants of the α-subunit of the amiloride-sensitive Na+ channel 1998
    1998 Inverse relationship of urinary cyclic GMP to blood pressure reactivity in the CARDIA study: Vasodilatory regulation of sympathetic vasoconstriction 1998
    1998 Liddie syndrome: An autosomal dominant form of human hypertension 1998
    1997 Evidence for an amiloride-insensitive Na+/H+ exchanger in rat renal cortical tubules 1997
    1997 Relationship of diastolic blood pressure with cyclic GMP excretion among young adults (the CARDIA study): Influence of a family history of hypertension 1997
    1997 The human angiotensinase C gene (HUMPCP) maps to 11q14 within 700 kb of D11S901: A candidate gene for essential hypertension 1997
    1997 Evidence for an amiloride-insensitive Na+/H+ exchanger in rat renal cortical tubules 1997
    1997 Acute renal failure in the 21st century: Recommendations for management and outcomes assessment 1997
    1997 Expression of the amiloride-sensitive sodium channel β subunit gene in human B lymphocytes 1997
    1997 Heterologous expression of rat NHE4: A highly amiloride-resistant Na+/H+ exchanger isoform 1997
    1997 Sodium transporters in health and disease 1997
    1996 Polymorphism in the beta subunit and Na+ transport 1996
    1996 Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresis 1996
    1996 Renal Na+/H+ exchanger isoforms and their regulation by thyroid hormone 1996
    1996 Biophysical properties of amiloride-sensitive sodium channels (ASSC) in human B lymphocytes 1996
    1996 Genetic association of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks 1996
    1996 Isolation and characterization of luminal and basolateral plasma membrane vesicles from the medullary thick ascending loop of Henle 1996
    1996 Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease 1996
    1996 Liddle's disease: Abnormal regulation of amiloride-sensitive Na+ channels by β-subunit mutation 1996
    1996 Peptide block of constitutively activated Na + channels in Liddle's disease 1996
    1996 Sticky business: cytoskeleton and Na+ transport. 1996
    1996 Stretch modulates amiloride sensitivity and cation selectivity of sodium channels in human B lymphocytes 1996
    1995 Immunopurification and functional reconstitution of a Na+ channel complex from rat lymphocytes 1995
    1995 Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients 1995
    1995 Liddle's syndrome: A public health menace? 1995
    1995 Liddle’s syndrome: Heritable human hypertension caused by mutations in the ß subnit of the epithelial sodium channel 1995
    1995 Mutational analysis of transmembrane histidines in the amiloride-sensitive Na+/H+exchanger 1995
    1994 Liddle's syndrome: Heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel 1994
    1994 Liddle syndrome: Clinical and cellular abnormalities 1994
    1994 G-proteins modulate amiloride-sensitive sodium channels 1994
    1994 Liddle's Syndrome Revisited – A Disorder of Sodium Reabsorption in the Distal Tubule 1994
    1994 Analysis of the genetic contamination of salt-sensitive Dahl/Rapp rats 1994
    1994 Renal apical membrane sodium-hydrogen exchange in genetic salt-sensitive hypertension 1994
    1993 Amiloride-sensitive sodium conductance in human B lymphoid cells 1993
    1993 Amiloride-sensitive sodium conductance in human B lymphoid cells 1993
    1993 Chromosomal Localization of Angiotensin II Type 1 Receptor Isoforms in the Rat 1993
    1993 Cytosolic pH sensitivity of an expressed human NHE-1 Na + -H + exchanger 1993
    1993 Liddle's syndrome: 30 years later 1993
    1991 IgA nephropathy in blacks: Studies of IgA2 allotypes and clinical course 1991
    1990 Mechanism of H+ secretion in the proximal convoluted tubule 1990
    1989 Distinct epitopes on amiloride 1989
    1989 Accumulation of weak base in gastric mucosa provides evidence for an acidic storage compartment 1989
    1989 K-Cl cotransport systems 1989
    1989 Pharmacokinetics of esmolol and ASL-8123 in renal failure 1989
    1989 Poles apart. A Forefront Symposium on the Organization of Membrane Polarity in Epithelial Cells sponsored by the International Society of Nephrology, the Swiss National Science Fund, and the 450th Anniversary Fund of the University of Lausanne, Arolla, Switzerland, July 2-6, 1989. 1989
    1988 Adrenocortical function in the acquired immunodeficiency syndrome (AIDS) 1988
    1988 Idiopathic pulmonary fibrosis 1988
    1988 Interactions of chloride and amiloride with the renal Na+/H+ antiporter 1988
    1988 Pheochromocytoma - Recent advances in diagnosis and treatment 1988
    1988 The clinical significance of water pollution 1988
    1988 Uremic acidosis 1988
    1987 Advances in the prenatal diagnosis of sickle cell anemia 1987
    1987 The effects of cycloheximide on Na+/H+ antiporter activity in cultured opossum kidney cells 1987
    1987 Activation of ion transport systems during cell volume regulation 1987
    1987 Acute pancreatitis 1987
    1987 Biochemical and clinical aspects of amyloidosis 1987
    1987 Current concepts in the treatment of tuberculosis 1987
    1987 K-C1 transport systems in rabbit renal basolateral membrane vesicles 1987
    1987 K-C1 transport systems in rabbit renal basolateral membrane vesicles 1987
    1987 N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, amiloride analogues, and renal Na+/H+ antiporter 1987
    1987 New approaches to treating systemic lupus erythematosus 1987
    1987 Parallel adaptation of the rabbit renal cortical sodium/proton antiporter and sodium/bicarbonate cotransporter in metabolic acidosis and alkalosis. 1987
    1986 Downwind update - a discourse on matters gaseous 1986
    1986 Electrically neutral Na+-H+ exchange in endosomes obtained from rabbit renal cortex 1986
    1986 Atrial natriuretic factor 1986
    1986 Electrogenic sodium/bicarbonate cotransport in rabbit renal cortical basolateral membrane vesicles 1986
    1986 Exercise and coronary artery disease - what should we be recommending to our patients (and ourselves)? 1986
    1986 Parathyroid hormone inhibition of Na+-H+ antiporter activity in a cultured renal cell line 1986
    1986 The effects of nicardipine in hypertensive subjects with impaired renal function 1986
    1986 The pathogenesis and prevention of diabetic nephropathy 1986
    1985 Primary hepatocellular carcinoma - Recent advances and future prospects 1985
    1985 Biologic Regulation of Na/H Antiporter Activity in a Cultured Kidney Cell Line: Effects of Parathyroid Hormone (PTH) 1985
    1985 Diagnosis and management of lower gastrointestinal tract hemorrhage 1985
    1985 Effects of carboxyl activation by ethoxycarbonyl-ethoxy-dihydroquinoline (EEDQ) on the Na/H antiporter in rabbit renal brush border membrane vesicles (BBMV) 1985
    1985 KCl countertransport in rabbit renal cortical basolateral membrane vesicles 1985
    1985 Regulation of the Activity of the Na+‐H+ Antiporter in Brush‐Border Membrane Vesicles from the Proximal Tubule 1985
    1985 Stress and medical training 1985
    1985 Therapeutic strategies in congestive heart failure and the new inotrope-vasodilator agents 1985
    1984 Hyperkalemia 1984
    1984 Ion transport processes in apical membranes of epithelia 1984
    1984 Increased Vmax for Na+/H+ antiporter activity in proximal tubule brush border vesicles from rabbits with metabolic acidosis. 1984
    1984 Na+/H+ antiporter in membrane populations resolved from a renal brush border vesicle preparation. 1984
    1984 Na-Cl cotransport in the renal medullary thick ascending limb of Henle's loop (TALH): Lack of potassium stimulation 1984
    1984 Na+/H+antiporter in membrane populations resolved from a renal brush border vesicle preparation 1984
    1984 Paget's disease of bone 1984
    1984 Problems in diagnosing pneumonia 1984
    1984 The design of rational combination chemotherapy for cancer 1984
    1983 Hypoglycemia: A pitfall of insulin therapy 1983
    1983 Liver transplantation 1983
    1983 Familial colonic cancer syndromes 1983
    1983 Effects of chloride gradients on total CO2 flux in the rabbit cortical collecting tubule. 1983
    1983 Asymmetrical distributions of the Na+/H+antiporter in the renal proximal tubule epithelial cell 1983
    1983 Effects of chloride gradients on total CO2flux in the rabbit cortical collecting tubule 1983
    1983 Mixed type inhibition of the renal Na+/H+ antiporter by the Li+ and amiloride. Evidence for a modifier site 1983
    1983 Osteoporosis. Part II. Prevention of bone loss and fractures in women and risks of menopausal estrogen therapy 1983
    1983 Pemphigus 1983
    1983 Use of diuretics in the treatment of cirrhotic ascites 1983
    1982 Na+/H+ antiporter of brush border vesicles: studies with acridine orange uptake. 1982
    1982 Sodium uptake mechanisms in brush-border membrane vesicles prepared from rabbit renal cortex 1982
    1982 Acidification in the in vitro perfused tubule 1982
    1982 Anion permeabilities of the isolated perfused rabbit proximal tubule 1982
    1982 Anion permeabilities of the isolated perfused rabbit proximal tubule 1982
    1982 Na+/H+antiporter of brush border vesicles: Studies with acridine orange uptake 1982
    1982 NaCl entry mechanisms in the luminal membrane of the renal tubule 1982
    1982 NaCl entry mechanisms in the luminal membrane of the renal tubule 1982
    1981 Proton gradients in renal cortex brush-border membrane vesicles. Demonstration of a rheogenic proton flux with acridine orange. 1981
    1981 Chloride uptake by brush border membrane vesicles isolated from rabbit renal cortex. Coupling to proton gradients and K+ diffusion potentials 1981
    1981 Effects of chloride (C1) gradients on total CO2flux in cortical collecting tubules (CCTS) 1981
    1979 Effect of acetazolamide on bicarbonate reabsorption in the proximal tubule of the rat 1979
    1979 Treatment of Hyperuricemia and Gout 1979
    1979 Carbonic anhydrase-dependent bicarbonate reabsorption in the rat proximal tubule 1979
    1979 Carbonic anhydrase-dependent bicarbonate reabsorption in the rat proximal tubule. 1979
    1979 Effect of acetazolamide on bicarbonate reabsorption in the proximal tubule of the rat 1979
    1979 Effects of anion-transport inhibitors on NaCl reabsorption in the rat superficial proximal convoluted tubule 1979
    1979 Proton secretion by the kidney. 1979
    1978 Contribution of leaked load to solute transport by renal tubules. 1978
    1978 Contribution of leaked load to solute transport by renal tubules 1978
    1978 Effects of acetazolamide (ACTZ) on total CO2reabsorption in the rat 1978
    1978 Ion selectivity and proximal salt reabsorption 1978
    1978 Ion selectivity and proximal salt reabsorption 1978
    1978 Luminal furosemide inhibits NaCl reabsorption in the superficial proximal tubule 1978
    1978 Occupancy of aldosterone binding sites in rat kidney cytosol 1978
    1977 Dual effects of diuretics on volume reabsorption by the proximal tubule 1977
    1977 Urinary acidification: CO2transport by the rabbit proximal straight tubule 1977
    1975 Measurement of Picomole Amounts of Carbon Dioxide by Calorimetry 1975
    1975 Spirolactone binding by aldosterone receptors in rat kidney cytosol 1975

    Book

    Year Title Altmetric
    2012 Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis.  Ed. 178.  2012

    Chapter

    Year Title Altmetric
    2010 Renal manifestations of fabry disease.  211-243. 2010

    Research Overview

  • Rare renal diseases
    Chronic Kidney Disease
    Acute Kidney Injury
  • Principal Investigator On

  • Private Grant  awarded by Genzyme Corporation 2004 - 2017
  • Private Grant  awarded by AMGEN, INC. 2008 - 2016
  • Private Grant  awarded by Genzyme Corporation 2007 - 2015
  • Private Grant  awarded by Gilead Sciences 2015
  • Private Grant  awarded by Genzyme Corporation 2014
  • Private Grant  awarded by Bayer HealthCare 2013 - 2014
  • Private Grant  awarded by Genzyme Corporation 2014
  • Private Grant  awarded by AMICUS THERAPEUTICS, INC 2011 - 2013
  • Private Grant  awarded by Genzyme Corporation 2013
  • Private Grant  awarded by Genzyme Corporation 2012
  • Private Grant  awarded by Genzyme Corporation 2011
  • Education And Training

  • UCSF Medical Center, Internship 1971
  • UCSF Medical Center, Residency 1972
  • UCSF Medical Center, Postdoctoral Fellowship 1973
  • Full Name

  • David Warnock